{"task_id": "b8129e6887d069b2", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 51/464)", "text": "ONT\u2019D)\nCLINICAL FEATURES (CONT\u2019D)\n36\nHeart Failure\n\n--- Page 58 ---\nCLINICAL FEATURES (CONT\u2019D)\nabsence of smoking or CAD. Normal radiographic\nheart size is helpful if present\nAPPROACH\n\u2018\u2018in patients without known systolic\ndysfunction, \u00061 finding of increased filling pres\nsure can exclude diagnosis, \u00053 findings suggests\nincreased filling pressure. In patients with known\nsystolic\ndysfunction,\nabsence\nof\nfinding\nof\nincreased filling pressure can exclude diagnosis,\n\u00051 finding suggests increased filling pressure.\nFor systolic dysfunction, can exclude diagnosis if\nno abnormal findings, including no sign of\nincreased filling pressure are present (LR\n0.1).\n\u00053 findings are needed to confirm the diagnosis\n(LR+ 14)\u2019\u2019\nJAMA 1997 277:21\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, troponin/CK \u00043,\nBNP, D dimer, TSH, albumin\n\u0002\nIMAGING\nCXR, echocardiogram (check E/A ratio\nif diastolic dysfunction)\n\u0002 ECG\nSPECIAL\n\u0002\nFURTHER IMAGING\nMIBI, MUGA\n\u0002\nSTRESS TEST\nto assess ischemic heart disease\n\u0002\nCARDIAC CATHETERIZATION\n\u0002 ABG\nif severe dyspnea\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nB TYPE NATRIURETIC PEPTIDE\n\u0002\nDIAGNOSIS\nin addition to heart failure, BNP is also\nelevated with PE, pulmonary hypertension, LVH,\nACS, AF, renal failure, overload, and sepsis\nBNP\nHeart Failure diagnosis\n<100 pg/mL\nUnlikely\n100 250 pg/mL\nCompensated LV dysfunction\n250 500 pg/mL\nHF with both diastolic and\nsystolic dysfunction\n500 1000 pg/mL\nDecompensated HF\n>1000 pg/mL\nHigh risk of substantial HF\n\u0002\nPROGNOSIS\nBNP >80th percentile is associated\nwith a >50% increase in long term mortality\nHF PROGNOSIS\n33% 1 year mortality, 75% 6 year\nmortality\nACUTE MANAGEMENT\nABC\nO2 to keep sat >95%, IV\u2019s\nSYMPTOM CONTROL\nwLMNOPw Lasix/furose\nmide 20 100 mg IV PRN, Morphine 2 5 mg IV PRN,\nNitroglycerin 0.4 mg SL PRN, O2, Position (upright)\nLONG TERM MANAGEMENT\nwDDDDw\nDIET\nlow salt (<100 mmol/day, 1.5 2 g/day), fluid\nrestriction (1.5 2 L/day)\nDIURETICS\nfurosemide 20 100 IV/PO daily BID\nwith daily adjustments (try to use smallest dose possi\nble to allow ACE inhibitor) \u0007 metolazone 2.5 5 mg\nPO\n30\nmin\nbefore\nfurosemide,\nspironolactone\n12.5 50 mg PO daily or eplerenone 25 50 mg PO daily\nVASODILATORS\nACE inhibitor (captopril 6.25 50 mg\nPO TID, enalapril 2.5 20 mg PO BID, ramipril 2.5 10 mg\nPO daily,lisinopril 2.5 20mgPOdaily,perindopril2 8mg\nPO daily). ARB (valsartan 40 160 mg PO BID, candesar\ntan 8 32 mg PO daily). Hydralazine 10 mg PO QID and\nnitropatch 0.4 mg PO daily. b blockers (metoprolol\n50 100 mg PO BID, carvedilol 3.125 25 mg PO BID,\nbisoprolol 2.5 10 mg PO daily)\nDIGITALIS\ndigoxin 0.125 0.25 mg PO daily\nTREAT UNDERLYING CAUSE\nCAD (CABG), aortic\nstenosis (AV replacement), sleep apnea (CPAP)\nDEVICES\nif ejection fraction <30 35%, consider\ncardiac resynchronization therapy (CRT/biventri\ncular pacing) \u0007 implantable cardioerter defibrilla\ntors (ICD). Ventricular assist devices may also be\nconsidered in selected cases of refractory HF\nTREATMENT ISSUES\nACE INHIBITOR (Garg, JAMA 1995)\nhazard ratios\nfor total mortality 0.77 and mortality/hospitalization\n0.65 for any patients with LVEF <40%. Target dose =\nmaximum tolerated. Contraindications include SBP\n<80 mmHg, bilateral renal artery stenosis, severe\nrenal failure, and hyperkalemia\nARB (Jong, J Am Coll Cardiol 2002, CHARM)\ncon\nsider substitution with ARB if ACE inhibitor not toler\nated (e.g. cough). May also be used as adjunct to ACE\ninhibitor if b blocker not tolerated. Contraindications\nsimilar to ACE inhibitor\nHYDRALAZINE/NITRATES (VHEFT I and II, A HeFT)\nless effective than ACE inhibitor. Particularly useful for\npregnant patients, African Americans, or those who\ndeveloped renal insufficiency while on ACE inhibitor,\nor as add on therapy\nb BLOCKERS (Foody JAMA 2002)\nhazard ratios for\ntotal mortality 0.65 and mortality/hospitalization\n0.64. May worsen symptoms in first few weeks and\nmay take up to 1 year to see full effect in LVEF. Useful\nfor patients with NYHA II III (and stable IV) and LVEF\n<40%, also NYHA I, LVEF <40%, and post MI. Contra\nindications include fluid overload and severe asthma.\nStart only when patient euvolemic\nSPIRONOLACTONE (RALES 1999, EPHESUS 2003)\nhazard ratios for total mortality 0.7 and mortality/\nhospitalization 0.65. For patients with NYHA III IV,\nHeart Failure\n37", "text_length": 4241, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 51/464)", "type": "chunk", "chunk_index": 50, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.302164", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.303717", "status": "complete", "chunks_added": 3}